News
Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...
Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...
Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...
The stock should perform well beyond 2030 thanks to its impressive innovative abilities. With a constellation of ...
U.S. stock futures surged Sunday evening following news that Washington and Beijing had reached a trade agreement during high ...
The Oscar-nominated actress talks about playing the activist whose 1990s lawsuit demanding equal pay with her male colleagues went all the way to the Supreme Court, and how her own mother inspired her ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results